iShares US Pharmaceuticals ETF
112 hedge funds and large institutions have $104M invested in iShares US Pharmaceuticals ETF in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 15 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
6% more capital invested
Capital invested by funds: $98.2M → $104M (+$5.97M)
2% more funds holding
Funds holding: 110 → 112 (+2)
0.24% less ownership
Funds ownership: 78.45% → 78.21% (-0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFA
Arlington Financial Advisors
Santa Barbara,
California
|
+$2.33M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.45M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$1.07M |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$837K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$837K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.63M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.68M |
| 3 |
Truist Financial
Charlotte,
North Carolina
|
-$612K |
| 4 |
Goldman Sachs
New York
|
-$556K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$355K |
IHE Hedge Fund Activity: Q4 2021 in Review
112 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2021, worth a combined $104M — up 6.1% from $98.2M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IHE positions and 15 closed out — a net gain of 2 holders — while 30 added to existing stakes and 25 trimmed.
The largest buyer was Arlington Financial Advisors, opening a new position worth an estimated $2.33M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.63M sold.
- 112 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2021, up from 110 in Q3 2021.
- Funds reported $104M of iShares US Pharmaceuticals ETF stock for Q4 2021, up 6.1% quarter-over-quarter.
- 17 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2021 and 15 closed out, a net change of +2 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2021 was Arlington Financial Advisors, an estimated $2.33M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2021 was Citadel Advisors, an estimated $7.63M sold.
Based on aggregated 13F filings for Q4 2021.